Blurbs

B.Riley Financial Sticks to Its Buy Rating for Altimmune (ALT)

In a report released today, Mayank Mamtani from B.Riley Financial reiterated a Buy rating on Altimmune (ALTResearch Report), with a price target of $26.00. The company’s shares opened today at $12.21.

Mamtani covers the Healthcare sector, focusing on stocks such as Altimmune, Novavax, and Intercept Pharma. According to TipRanks, Mamtani has an average return of -30.4% and a 21.02% success rate on recommended stocks.

Currently, the analyst consensus on Altimmune is a Strong Buy with an average price target of $31.67.

See Insiders’ Hot Stocks on TipRanks >>

Based on Altimmune’s latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $8 thousand and a GAAP net loss of $20.11 million. In comparison, last year the company earned a revenue of $137 thousand and had a GAAP net loss of $24.83 million

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

The Group is development stage company which intend to acquire an operating business, through a merger, capital stock exchange, asset acquisition or other similar business combination. The Group does not have any activities.

Read More on ALT:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More